A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

June 24, 2020

Primary Completion Date

November 10, 2023

Study Completion Date

November 10, 2023

Conditions

Relapsed and/or Refractory Multiple Myeloma

Interventions

DRUG

TAK-573

TAK-573 intravenous infusion.

DRUG

Pomalidomide

Pomalidomide capsules orally.

DRUG

Bortezomib

Bortezomib injection subcutaneously.

DRUG

Cyclophosphamide

Cyclophosphamide tablets orally.

DRUG

Dexamethasone

Dexamethasone tablets orally.